Pharmacotherapy of social anxiety disorder: An algorithm for primary care - 2001

Primary Care Psychiatry

Volumn 7, Issue 3, 2001, Pages 107-110

  Stein, D J ^a   Kasper, S ^a   Matsunaga, H ^a   Osser, D N ^a   Stein, M B ^a   Van Ameringen, M ^a   Versiani, M ^a   Westenberg, H ^a   Zhang, M ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Algorithm; Guidelines; Pharmacotherapy; Primary care; Social anxiety disorder

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; HERBACEOUS AGENT; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; NON PRESCRIPTION DRUG; PAROXETINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALGORITHM; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; DISABILITY; DISEASE RESISTANCE; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENERAL PRACTITIONER; HEALTH CARE COST; HUMAN; MAINTENANCE THERAPY; MEDICAL EXPERT; MEDICAL LITERATURE; PREVALENCE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; QUESTIONNAIRE; WITHDRAWAL SYNDROME;

EID: 0034766792     PISSN: 13552570     EISSN: None     Source Type: Journal    
DOI: 10.1185/135525701317094368     Document Type: Article

References (35)

1. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
2. Functional impairment of social phobia
3. The economic burden of anxiety disorders in the 1990s
4. The economic and emotional impact of social anxiety disorder
5. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey
6. Social phobia: Comorbidity and morbidity in an epidemiologic sample
7. Evidence-based clinical behavior analysis, evidence-based medicine and the Cochrane collaboration
8. The expert consensus guideline series: An overview
9. Algorithms for the pharmacotherapy of anxiety disorders in patients with chemical abuse and dependence
10. Clinical practice guidelines: Good news, bad news, or no news
11. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety
12. An algorithm for the pharmacotherapy of social phobia
13. Social phobia
14. Social phobia in general health care: An unrecognised undertreated disabling disorder
15. Psychotherapy in the overall management strategy for social anxiety disorder
16. Practice parameters for the assessment and treatment of children and adolescents with anxiety disorders. AACAP
17. Risk-benefit assessment of drug therapies for anxiety disorders in children and adolescents
18. The efficacy of the selective serotonin reuptake inhibitors in social phobia (social anxiety disorders): A meta-analysis of randomized controlled trials
19. Treatment of social phobia with clonazepam and placebo
20. Phenelzine vs atenolol in social phobia: A placebo-controlled comparison
21. Paroxetine in the treatment of social phobia/social anxiety disorder: Randomized, double-blind, placebo-controlled study
22. Venlafaxine in social phobia: A study in selective serotonin reuptake inhibitor non-responders
23. Venlafaxine in social phobia
24. Nefazodone in social phobia
25. Moclobemide in the treatment of social phobia
26. Discontinuation of clonazepam in the treatment of social phobia
27. Treatment of social phobia with gabapentin: A placebo-controlled study
28. Psychometric properties of the Social Phobia Inventory
29. Social phobia
30. Social phobia: Long-term treatment outcome and prediction of response - A moclobemide study
31. Buspirone augmentation of SSRIs in social phobia